CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

David Meeker

Chairman, President and Chief Executive Officer, Rhythm Pharmaceuticals, Inc.

Search every verified David Meeker interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. David Meeker, Chairman, President, and CEO of Rhythm Pharmaceuticals, has been active in discussing the company's recent regulatory and clinical developments. In March 2026, he announced the FDA approval of Imcivree (setmelanotide) for acquired hypothalamic obesity, describing it as an important moment for patients with this condition. He noted that the company plans to engage with CMS regarding coverage and acknowledged that while the approval was expected, the company had hoped for a different outcome in certain discussions. In a June 2026 interview, Meeker emphasized the role of patients and caregivers in the diagnostic journey, stating that the process of reaching awareness and a diagnosis should be greatly accelerated, and encouraged patients to advocate for their own care and engage with the company's patient services group. Meeker has also commented on broader industry issues. In April 2025, he stated that tariffs would not directly impact Rhythm but could pressure the biotech sector, and he expressed concern that FDA layoffs might slow drug approvals for rare diseases. He has previously advocated for genetic testing in early-onset obesity, describing it as a key diagnostic clue, and has discussed the importance of considering markets outside the United States, noting that 95% of sick people are outside the country. In earlier appearances, Meeker discussed the business model for orphan drugs, the value of drug development, and the role of patient advocacy in advancing rare disease research.

Recent appearances

  • Dr. David Meeker, CEO of Rhythm: patients & caregivers have power in the diagnostic journey

    June 26, 2026 · 📺 Raymond A Wood Foundation

    “The process of getting to awareness and a diagnosis should be greatly accelerated.” — Dr. David Meeker, CEO of Rhythm Pharmaceuticals The approval of setmelanotide represents more than a new treatment option — it represents a new opportunity for patients and families to recognize symptoms, seek answers, and advocate for care. For many survivors living with acquired hypothalamic obesity, the journey can feel isolating and confusing. Patients may know something is wrong, but not understand why they experience relentless hunger, rapid weight gain, or metabolic changes after treatment for a h…

    Watch on YouTube ↗

  • Rhythm Pharmaceuticals IMCIVREE Approved by FDA for Acquired Hypothalamic Obesity | March 19, 2026

    March 21, 2026 · 📺 i101

    Rhythm Pharmaceuticals IMCIVREE Approved by FDA for Acquired Hypothalamic Obesity | March 19, 2026. If you find our work useful, please support us by purchasing a Super Thanks— it truly helps us a lot. #earningscall #StockMarketNews #conferenceCall Earnings Call | Earnings Conference Call | Earnings concall | concall | quarterly results | Stock News | Full Year results | Fiscal Year results | investment news | stock latest news If you want us to remove your company's earnings call or any other conference call, please reach out to [email protected].

    Watch on YouTube ↗

  • Meeker: Tariffs won't hit us hard, but they pressure the whole sector

    April 11, 2025 · 📺 CNBC Television

    Dr. David Meeker, CEO of Rhythm Pharma, says tariffs won't directly impact them but could stress the biotech sector. He warns FDA layoffs may slow drug approvals for rare diseases.

    Watch on YouTube ↗

  • FDA Approval of Setmelanotide for Patients 2 Years and Older With MC4R Pathway Diseases

    February 03, 2025 · 📺 CheckRare

    David Meeker, MD, Chief Executive Officer of Rhythm Pharmaceuticals, discusses the U.S. Food and Drug Administration’s (FDA) approval of setmelamotide for children 2 years and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. BBS, POMC, PCSK1, and LEPR deficiencies are rare melanocortin-1 receptor (MC4R) pathway diseases. Common characteristics include hyperphagia, impaired satiety, persistent and abn…

    Watch on YouTube ↗

  • USAIC Panel 2024: Rare & Neuro Diseases

    November 12, 2024 · 📺 USAIC

    Rare & Neuro Diseases Panelists: Dr. David Meeker, Chairman & CEO, Rhythm Pharmaceuticals Dr. Ed Kaye, President & CEO, Stoke Therapeutics Dr. James Wilson, Director- Gene Therapy Program, University of Pennsylvania Josh Mandel-Brehm, President & CEO, CAMP4 Dr. Priya Singhal, Executive Vice President & Head of Development, Biogen Moderator: Dr. William Chin, Professor of Medicine, Emeritus, Harvard Medical School

    Watch on YouTube ↗

  • Rare Disease Panel

    March 24, 2022 · 📺 USAIC

    Panelists: Dr. David Meeker, Chairman & CEO, Rhythm Pharmaceuticals Dr. Frank Bennett, Chief Scientific Officer, Ionis Pharmaceuticals Dr. John Orloff, Head of Research & Development, Alexion Dr. Katherine High, President - Therapeutics, AskBio Majid Jafar, Co-Founder, Loulou Foundation Moderator: Dr. Alfred Sandrock, Head of Research and Development, Biogen

    Watch on YouTube ↗

  • Patient’s Role in Drug Development Dr David Meeker 2020 FAST Science Summit

    January 02, 2021 · 📺 FAST

    Disclaimer: The information contained in these slides is provided for informational purposes only and should not be construed as medical, legal, financial, or any other type of professional advice. The views and opinions expressed in this presentation and on the following slides are solely those of the presenter and not necessarily those of FAST. FAST does not guarantee the accuracy or reliability of the information provided herein. Under no circumstances, including negligence, shall FAST or its officers, directors, employees, partners, or licensors be liable for any direct, indirect, incide…

    Watch on YouTube ↗

  • Whitehead Connects: An Evening with David Meeker

    January 10, 2019 · 📺 Whitehead Institute for Biomedical Research

    During this Whitehead Connects presentation, Dr. David Meeker discusses innovation and biopharmaceutical pricing. Dr. Meeker is the President & CEO of KSQ, a biotech company with a proprietary CRISPRomics drug discovery engine. Dr. Meeker was formerly the President and CEO of Genzyme, a Sanofi company, a position he assumed when Genzyme merged with Sanofi in 2011. He was also a member of the executive committee. Dr. Meeker is the Chairman of the Board of Rhythm Pharmaceuticals and Trevi Therapeutics and a member of the board at Myokardia. He also serves on the boards of the Biomedical Scienc…

    Watch on YouTube ↗

  • Lifecycle MA - Value of Drug Development

    June 16, 2016 · 📺 MassBio

    Fireside Chat: David Meeker & Rob Weisman Tuesday, June 7, 2016.

    Watch on YouTube ↗

  • From large to small: the critical elements of orphan drug success / David Meeker, COO, Genzyme

    February 03, 2012 · 📺 Orphan Drugs

    How are the research objectives of all sized organisations becoming merged? What do different organisational cultures and sizes think about being successful?

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →